An inadequate amount of sleep has been associated with higher risks of obesity, heart disease, diabetes, and death. Now colon cancer can be added to the list.
In a ground-breaking new study published in the Feb. 15, 2011 issue of the journal Cance…
Cancer researchers at The Peggy and Charles Stephenson Oklahoma Cancer Center have found a way to stop early stage pancreatic cancer in research models — a result that has far-reaching implications in chemoprevention for high-risk patients.
…
A more personalized treatment for people with a type of metastatic liver cancer –hepatocellular carcinoma — may be possible by targeting the protein c-Met, according to Penn State College of Medicine researchers. Hepatocellular carcinoma (HCC) is …
COLUMBUS, Ohio — The wasting disease associated with some cancers that is typically seen affecting skeletal muscles can also cause significant damage to the heart, new research in mice suggests.
Before now, cachexia, characterized by muscle wa…
DETROIT — An incisionless robotic surgical procedure is offering patients a new option to remove certain head and neck cancer tumors without visible scarring, while preserving speech and the ability to eat.
Henry Ford Hospital in Detroit i…
Researchers from Ohio State University found that a common pain relief medication seems to increase the effectiveness of a drug used to treat skin cancer. Experiments in mice showed that the combination of celecoxib — a prescription-only non-steroidal anti-inflammatory drug (NSAID) — and a cream commonly used to treat nonmelanoma skin cancer was up to 35 percent more effective in reducing the number of skin cancer tumors than treating such lesions with the cream alone.
New research suggests that combining the chemotherapy drug paclitaxel with very low doses of the HIV-fighting drug AZT may shrink or even eradicate certain types of cancer tumors. Using both drugs in mice helped inhibit the enzyme telomerase, a component critical to the livelihood of some cancer cells. Telomerase helps to build and maintain telomeres ? protective strands of DNA at each end of a chromosome.
The presence of tumor-infiltrating lymphocytes predicts the length of remission after chemotherapy and the overall survival of patients with ovarian cancer, according to researchers from the Abramson Cancer Center and the Center on Women’s Health at the University of Pennsylvania School of Medicine. Their findings, which are presented in the January 16th issue of the New England Journal of Medicine, constitute the first proof that a spontaneous immune response against the tumor dramatically impacts the clinical course of ovarian cancer. These novel findings generate hope that immune therapies may significantly prolong the response to chemotherapy and improve the survival of patients with advanced ovarian carcinoma.